By Digifin Pty Ltd · About this coverage
Key Points
- Q3 total revenue of approximately $26.1 million, up 53% year over year
- Full-year 2026 revenue guidance raised to $92 million to $94 million, from $86 million to $89 million
- Gross margin of 84.0%, up 270 basis points
- Net loss of $6.2 million, against $13.2 million a year earlier
- Going concern qualification removed in the Form 10-Q
About AVITA Medical (ASX:AVH)
AVITA Medical, Inc. is a medical technology company headquartered in Valencia, California, with shares listed on the Nasdaq and CHESS Depositary Interests quoted on the ASX. It develops and sells wound care products, led by the RECELL system, which prepares a suspension of a patient's own skin cells for treating burns and other skin wounds.
AVITA Medical (ASX:AVH) released its third-quarter results to raise its full-year 2026 revenue guidance and to report that management has removed the going concern qualification from its Quarterly Report on Form 10-Q.
Total revenue was approximately $26.1 million for the quarter ended September 30, 2026, up 53% on $17.1 million a year earlier and up 20% sequentially. RECELL U.S. revenue was $22.4 million and Cohealyx revenue $2.1 million. Gross margin was 84.0%, up 270 basis points. Operating expenses were $24.6 million, and the net loss was $6.2 million, or $0.20 per share, against $13.2 million a year earlier. Net cash use was approximately $0.6 million, and cash, cash equivalents and marketable securities were approximately $10.5 million at quarter end. Full-year revenue guidance is now $92 million to $94 million, from $86 million to $89 million, which the company says implies fourth-quarter revenue of $24.9 to $26.9 million. After reaching the $85 million trailing twelve-month revenue milestone, AVITA drew the remaining $10.0 million tranche of its credit facility with Perceptive Advisors LLC after quarter end, bringing total borrowings under the facility to $60 million.
Cash flow breakeven in the fourth quarter of 2026 remains an expectation, not a result. The net loss included $2.1 million of non-cash warrant revaluation expense. The release does not name the currency of its dollar figures.
Source: AVITA Medical, Inc. (ASX:AVH), 6 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.